Patents Assigned to Mochida Pharmaceutical Co., Ltd.
  • Patent number: 9453015
    Abstract: It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: September 27, 2016
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Akihiro Okano, Fumihiko Saitoh
  • Patent number: 9452150
    Abstract: A composition in which a preparation of the composition itself has an excellent disintegratability in the right place and excellent active ingredient releasability within the digestive tract, the active ingredient and the preparation itself have long-term stability, excellent ease of operation such as manufacturability and filling into containers, an amount sufficient for achieving physiological effects can be easily taken and swallowed, and can be absorbed rapidly from the digestive tract, thus the physiological effect can be expected. The composition is an easy-release jelly composition containing an emulsified polyvalent unsaturated fatty acid or derivative thereof in an amount exceedingly 10 mass % and further containing an emulsifying agent and a gallant. The easy-release jelly composition includes an emulsified polyunsaturated fatty acid or derivative thereof in an amount greater than 10 wt %, an emulsifying agent, and a gelling agent.
    Type: Grant
    Filed: August 18, 2005
    Date of Patent: September 27, 2016
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroki Ueshima, Shigeharu Suzuki, Naomi Yokomizo, Atsushi Sato, Hirosato Fujii
  • Patent number: 9440970
    Abstract: It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: September 13, 2016
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Akihiro Okano, Muneyoshi Makabe
  • Publication number: 20160169889
    Abstract: Provided are a method for detecting respiratory infection associated with bacterial infection, a method for selecting patients with respiratory infection to receive an antibiotic, and a method for determining the timing for ending administration of an antibiotic to a patient with respiratory infection receiving the antibiotic, wherein said methods are characterized in that they are able to appropriately select patients with respiratory infection to whom the antibiotic is to be administered, to adjust the administration period of the antibiotic, and to treat respiratory infection associated with bacterial infection, and in that a measured value of sCD14-ST in urine is used as an indication.
    Type: Application
    Filed: February 19, 2016
    Publication date: June 16, 2016
    Applicant: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon Shirakawa
  • Publication number: 20160158184
    Abstract: A self-emulsifying composition which comprises, when taking the total amount of the self-emulsifying composition as 100 mass %, 70 to 90 mass % of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids, pharmaceutically acceptable salts thereof, and esters of the same, 0.5 to 6 mass % of water and 1 to 29 mass % of an emulsifying agent that comprises a polyoxyethylene sorbitan fatty acid ester (and that further contains a polyoxyl castor oil optionally, with the proviso that the emulsifying agent does not include lecithin) and which contains 3 to 40 parts by mass of lecithin relative to 100 parts by weight of the ?3 polyunsaturated fatty acid or the like. This self-emulsifying composition exhibits excellent self-emulsifying properties, composition dispersibility, emulsion stability and absorbability, and does not contain ethanol or a polyhydric alcohol or contains the same only in a low concentration. The self-emulsifying composition is useful for food and medicine.
    Type: Application
    Filed: July 17, 2014
    Publication date: June 9, 2016
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hiromitsu ITO, Hirosato FUJII, Motoo YAMAGATA
  • Publication number: 20160151319
    Abstract: A self-emulsifying composition contains: 70 to 90% by weight in total of one or more compounds selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 1 to 29% by weight of an emulsifying agent selected from among a polyoxyethylene sorbitan fatty acid ester, a sorbitan fatty acid ester, a glycerin fatty acid ester and a polyoxyl castor oil; and 0.5 to 6% by weight of water when the composition is defined to be 100% by weight as a whole. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.
    Type: Application
    Filed: July 17, 2014
    Publication date: June 2, 2016
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shigeru KIMURA, Hiromitsu ITO, Hirosato FUJII, Motoo YAMAGATA
  • Patent number: 9345681
    Abstract: The present invention provides an agent for preventing the increase in a body weight (or for decreasing a body weight) or an anti-obesity agent each comprising at least one component selected from the group consisting of EPA and pharmaceutically acceptable salts, esters and derivatives thereof as an active ingredient for obesity in which the increase in the formation of hepatic lipid or the occurrence of fatty liver is mild, preferably the increase in the formation of hepatic lipid or the occurrence of fatty liver is not observed.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: May 24, 2016
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Takayuki Ishida, Hiroyuki Kawano
  • Publication number: 20160115542
    Abstract: Provided is FGF21 that is a metabolism-related biomarker reflecting the activation of Nrf2 in vivo. Also provided are a method for monitoring a response of a subject to which an Nrf2 activator is administered, said method comprising a step for measuring the FGF21 level, at a point during or after the administration of the Nrf2 activator, in a biosample that is derived from the subject, wherein an increase in the FGF21 level indicates a positive response to the administration of the Nrf2 activator, etc. According to the present invention, a metabolism-related biomarker that reflects the activation of Nrf2 in vivo is provided.
    Type: Application
    Filed: May 28, 2014
    Publication date: April 28, 2016
    Applicants: Mochida Pharmaceutical Co., Ltd., Tohoku University
    Inventors: Masayuki Yamamoto, Akira Uruno, Yuki Furusawa
  • Publication number: 20160089355
    Abstract: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.
    Type: Application
    Filed: December 9, 2015
    Publication date: March 31, 2016
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Mitsuhiro YOKOYAMA, Hideki ORIGASA, Masunori MATSUZAKI, Yuji MATSUZAWA, Yasushi SAITO
  • Patent number: 9297802
    Abstract: According to the method for detecting respiratory infection associated with bacterial infection of the present invention, the measured value of soluble CD14 antigen subtype (“sCD14-ST) in the urine sample can be used to select a patient with a respiratory infection to whom the antibiotic can be administered.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: March 29, 2016
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon Shirakawa
  • Patent number: 9291631
    Abstract: According to the method for detecting respiratory infection associated with bacterial infection of the present invention, the measured value of soluble CD14 antigen subtype (“sCD14-ST) in the blood sample can be used to select a patient with a respiratory infection to whom the antibiotic can be administered.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: March 22, 2016
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon Shirakawa
  • Publication number: 20160067309
    Abstract: A novel composition for regenerating a cartilage has been demanded, which can achieve a good effect of regenerating a hyaline cartilage that is a nearly normal cartilage without requiring the use of any transplanted cell. The present invention provides a composition for regenerating a cartilage, wherein (a) a monovalent metal salt of low endotoxin alginic acid and (b) SDF-1 are used in combination.
    Type: Application
    Filed: November 18, 2015
    Publication date: March 10, 2016
    Applicants: Mochida Pharmaceutical Co., Ltd., National University Corporation Hokkaido University
    Inventors: Norimasa IWASAKI, Atsushi SUKEGAWA, Akio MINAMI, Nobuo OHZAWA
  • Publication number: 20160045469
    Abstract: Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI.
    Type: Application
    Filed: October 29, 2015
    Publication date: February 18, 2016
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Mitsuhiro YOKOYAMA, Hideki ORIGASA, Masunori MATSUZAKI, Yuji MATSUZAWA, Yasushi SAITO, Yuichi ISHIKAWA, Shinichi OIKAWA, Jun SASAKI, Hitoshi HISHIDA, Hiroshige ITAKURA, Toru KITA, Akira KITABATAKE, Noriaki NAKAYA, Toshiie SAKATA, Kazuyuki SHIMADA, Kunio SHIRATO
  • Publication number: 20160030378
    Abstract: The disclosure provides for a method for treating a fatty liver disease or disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic; has normal or substantially normal biliary tract function; or has non or early stage hepatocyte apoptosis; and administering a therapeutically effective amount of a pharmaceutical composition comprising EPAs.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Tsuyoshi HARADA, Hideo KANEHIRO, Kiyoshi MIZUGUCHI
  • Patent number: 9233093
    Abstract: By using a composition for preventing onset and/or recurrence of stroke which contains ethyl icosapentate as its effective component, onset and/or recurrence of stroke is prevented, or in particular, the onset and/or recurrence of stroke in a hyperlipidemia patient who has been treated with HMG-CoA RI, or in particular the recurrence of stroke in a patient who is beyond six months after the onset of stroke, is prevented.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: January 12, 2016
    Assignee: MOCHIDA PHARMACEUTICALS CO., LTD.
    Inventors: Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito
  • Publication number: 20150368269
    Abstract: The present invention provides a compound of Formula (I) where A is a heterocycle ring system and B is a heterocycle ring system or aryl ring system, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Application
    Filed: December 16, 2013
    Publication date: December 24, 2015
    Applicants: Merck Sharp & Dohme Corp., Mochida Pharmaceutical Co., Ltd.
    Inventors: Cameron James Smith, Edward Sherer, Louis-Charles Campeau, James Balkovec, William John Greenlee, Derun Li, Liangqin Guo, Tin-Yau Chan, Yi-Heng Chen, Yili Chen, Samuel Chackalamannil, John Qiang Tan, Tomokazu Hirabayashi, Mika Sekioka
  • Patent number: 9216201
    Abstract: The present invention provides a composition for regenerating cartilage or treating a cartilage disease containing a monovalent metal salt of alginic acid for which the endotoxin level thereof has been lowered to an extent that does not substantially induce inflammation or fever. As a result, it is possible to provide a composition for regenerating cartilage that improves cartilage regenerative action and ease of application to a cartilage injury lesion, and a composition for treating a cartilage disease, which has the effects of protecting cartilage from mechanical irritation, inhibiting degenerative changes in cartilage caused by wear and inflammation, repairing a cartilage injury lesion, and inhibiting inflammation and pain of joint tissue.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: December 22, 2015
    Assignees: Mochida Pharmaceutical Co., Ltd., National University Corporation Hokkaido University
    Inventors: Norimasa Iwasaki, Akio Minami, Yasuhiko Kasahara, Tatsuya Igarashi, Daisuke Kawamura, Fumiyoshi Kasahara, Chihiro Miyajima, Nobuo Ohzawa, Mariko Imai
  • Patent number: 9198892
    Abstract: Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI.
    Type: Grant
    Filed: November 8, 2012
    Date of Patent: December 1, 2015
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Hiroshige Itakura, Toru Kita, Akira Kitabatake, Noriaki Nakaya, Toshiie Sakata, Kazuyuki Shimada, Kunio Shirato
  • Publication number: 20150329562
    Abstract: The present invention provides a compound of Formula (I) wherein R1, R2, R3 and R4 are independently H or C1-6 alkyl, provided that when R1, R2, and R3 are H, R4 is C1-6 alkyl, and when R1, R2, and R4 are H, R3 is C1-6 alkyl, and when R1, R3, and R4 are H, R2 is C1-6 alkyl, and when R2, R3, and R4 are H, R is C1-6 alkyl; and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes.
    Type: Application
    Filed: December 16, 2013
    Publication date: November 19, 2015
    Applicants: Merck Sharp & Dohme Corp., Mochida Pharmaceutical Co., Ltd.
    Inventors: Cameron James Smith, John Qiang Tan, Ting Zhang, James Balkovec, William John Greenlee, Liangqin Guo, Yi-Heng Chen, Yili Chen, Samuel Chackalamannil, Tomokazu Hirabayashi, Mika Sekioka
  • Publication number: 20150322056
    Abstract: The present invention provides a compound of Formula (I) wherein R1 is H or C1-6 alkyl, R2, is H or C1-6 alkyl or CH2OH, R3 is H or C1-6 alkyl, and R4 is H or C1-6 alkyl, provided that when R1, R2, and R3 are H, R4 is C1-6 alkyl, and when R1, R2, and R4 are H, then R3 is C1-6 alkyl, and when R1, R3, and R4 are H, R2 is C1-6 alkyl or —CH2OH, and when R2, R3, and R4 are H, then R1 is C1-6 alkyl; A is 1) a 9-10 membered bicyclic heterocycle having 1-3 heteroatoms independently selected from N, S and O, which 9-10 membered bicyclic heterocycle is unsubstituted or substituted with R5 and unsubstituted or substituted with R6 and unsubstituted or substituted with NH2, or 2) a 6-9 membered monocyclic or bicyclic carbocyclic ring system unsubstituted or substituted with R5, unsubstituted or substituted with R6, and unsubstituted or substituted with —CH2NH2; and B is 1) a 5- or 6-membered monocyclic heterocycle having 1 or 2 heteroatoms independently selected from N, S or O, which is unsubstituted or substitut
    Type: Application
    Filed: December 16, 2013
    Publication date: November 12, 2015
    Applicants: Mochida Pharmaceutical Co., Ltd., Merck Sharp & Dohme Corp.
    Inventors: Cameron James SMITH, John Qiang TAN, Ting ZHANG, James BALKOVEC, William John GREENLEE, Liangqin GUO, Yi-Heng CHEN, Yili CHEN, Jiayi XU, Samuel CHACKALAMANNIL, Tomokazu HIRABAYASHI, Hiroshi NAGASUE, Kouki OGAWA